Literature DB >> 32220217

Adeno-Associated Virus D-Sequence-Mediated Suppression of Expression of a Human Major Histocompatibility Class II Gene: Implications in the Development of Adeno-Associated Virus Vectors for Modulating Humoral Immune Response.

Hyung-Joo Kwon1, Keyun Qing2, Selvarangan Ponnazhagan3, Xu-Shan Wang4, David M Markusic5, Siddhant Gupte6, Shannon E Boye6, Arun Srivastava2,3,4,5,6,7.   

Abstract

A 20-nt long sequence, termed the D-sequence, in the adeno-associated virus (AAV) inverted terminal repeat was observed to share a partial sequence homology with the X-box in the regulatory region of the human leukocyte antigen DRA (HLA-DRA) promoter of the human major histocompatibility complex class II (MHC-II) genes. The D-sequence was also shown to specifically interact with the regulatory factor binding to the X-box (RFX), binding of which to the X-box is a critical step in the MHC-II gene expression, suggesting that D-sequence might compete for RFX transcription factor binding, thereby suppressing expression from the MHC-II promoter. In DNA-mediated transfection experiments, using a reporter gene under the control of the HLA-DRA promoter, D-sequence oligonucleotides were found to inhibit expression of the reporter gene expression in HeLa and 293 cells by ∼93% and 96%, respectively. No inhibition was observed when nonspecific synthetic oligonucleotides were used. D-sequence oligonucleotides had no effect on expression from the cytomegalovirus immediate-early gene promoter. Interferon-γ-mediated activation of MHC-II gene expression was also inhibited by D-sequence oligonucleotides as well as after infection with either the wild-type AAV or transduction with recombinant AAV vectors. These studies suggest that the D-sequence-mediated downregulation of the MHC-II gene expression may be exploited toward the development of novel AAV vectors capable of dampening the host humoral response, which has important implication in the optimal use of these vectors in human gene therapy.

Entities:  

Keywords:  AAV; MHC class II; gene expression; gene therapy; immune response

Year:  2020        PMID: 32220217      PMCID: PMC7232703          DOI: 10.1089/hum.2020.018

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  59 in total

1.  RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency.

Authors:  U M Nagarajan; P Louis-Plence; A DeSandro; R Nilsen; A Bushey; J M Boss
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

2.  Gene therapy for aromatic L-amino acid decarboxylase deficiency.

Authors:  Wuh-Liang Hwu; Shin-ichi Muramatsu; Sheng-Hong Tseng; Kai-Yuan Tzen; Ni-Chung Lee; Yin-Hsiu Chien; Richard O Snyder; Barry J Byrne; Chun-Hwei Tai; Ruey-Meei Wu
Journal:  Sci Transl Med       Date:  2012-05-16       Impact factor: 17.956

3.  Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo.

Authors:  K Qing; B Khuntirat; C Mah; D M Kube; X S Wang; S Ponnazhagan; S Zhou; V J Dwarki; M C Yoder; A Srivastava
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

4.  Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results.

Authors:  John Guy; William J Feuer; Janet L Davis; Vittorio Porciatti; Phillip J Gonzalez; Rajeshwari D Koilkonda; Huijun Yuan; William W Hauswirth; Byron L Lam
Journal:  Ophthalmology       Date:  2017-06-21       Impact factor: 12.079

5.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Z Wang; H-I Ma; J Li; L Sun; J Zhang; X Xiao
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

6.  Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

Authors:  K John Pasi; Savita Rangarajan; Nina Mitchell; Will Lester; Emily Symington; Bella Madan; Michael Laffan; Chris B Russell; Mingjin Li; Glenn F Pierce; Wing Y Wong
Journal:  N Engl J Med       Date:  2020-01-02       Impact factor: 91.245

7.  A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome).

Authors:  V Steimle; B Durand; E Barras; M Zufferey; M R Hadam; B Mach; W Reith
Journal:  Genes Dev       Date:  1995-05-01       Impact factor: 11.361

8.  Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.

Authors:  Brandon K Sack; Sherin Merchant; David M Markusic; Amit C Nathwani; Andrew M Davidoff; Barry J Byrne; Roland W Herzog
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

9.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.

Authors:  Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra
Journal:  Lancet       Date:  2014-01-16       Impact factor: 79.321

10.  A Novel Triple-Mutant AAV6 Capsid Induces Rapid and Potent Transgene Expression in the Muscle and Respiratory Tract of Mice.

Authors:  Laura P van Lieshout; Jakob M Domm; Tara N Rindler; Kathy L Frost; Debra L Sorensen; Sarah J Medina; Stephanie A Booth; James P Bridges; Sarah K Wootton
Journal:  Mol Ther Methods Clin Dev       Date:  2018-04-14       Impact factor: 6.698

View more
  3 in total

1.  Reply to "D" matters in recombinant AAV packaging.

Authors:  Jakob Shoti; Keyun Qing; Arun Srivastava
Journal:  Mol Ther       Date:  2021-08-25       Impact factor: 12.910

2.  Muscle regeneration affects Adeno Associated Virus 1 mediated transgene transcription.

Authors:  Sofia Benkhelifa-Ziyyat; Stéphanie Lorain; Amédée Mollard; Cécile Peccate; Anne Forand; Julie Chassagne; Laura Julien; Pierre Meunier; Zoheir Guesmia; Thibaut Marais; Marc Bitoun; France Piétri-Rouxel
Journal:  Sci Rep       Date:  2022-06-11       Impact factor: 4.996

Review 3.  Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.

Authors:  Thilo M Buck; Jan Wijnholds
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.